SC 13G/A: SUPERNUS PHARMACEUTICALS, INC.
Ticker: SUPN · Form: SC 13G/A · Filed: 2024-02-14T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by SUPERNUS PHARMACEUTICALS, INC..
Risk Assessment
Risk Level: low
Filing Stats: 1,519 words · 6 min read · ~5 pages · Grade level 10.9 · Accepted 2024-02-14 14:33:26
Key Financial Figures
- $0.001 — INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class o
Filing Documents
- armistice-supn123123a4.htm (SC 13G/A) — 87KB
- 0001172661-24-001241.txt ( ) — 89KB
(a)Name of Issuer
Item 1. (a)Name of Issuer SUPERNUS PHARMACEUTICALS, INC.
(b)Address of Issuer’s Principal
Item 1. (b)Address of Issuer’s Principal Executive Offices 9715 Key West Avenue Rockville, MD 20850
(a)Names of Person Filing
Item 2. (a)Names of Person Filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b) Address of Principal Business Office
Item 2. (b) Address of Principal Business Office: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c) Citizenship
Item 2. (c) Citizenship: Armistice Capital, LLC - Delaware Steven Boyd - United States of America
(d)Title of Class of Securities
Item 2. (d)Title of Class of Securities Common Stock, $0.001 par value per share (“Shares”)
(e) CUSIP No
Item 2. (e) CUSIP No.: 868459108 CUSIP No. 868459108 SCHEDULE 13G/A Page 5 of 8 Pages
If
Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) x An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: CUSIP No. 868459108 SCHEDULE 13G/A Page 6 of 8 Pages Item 4.Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned as of December 31, 2023: Armistice Capital, LLC - 4,650,000 Steven Boyd - 4,650,000 (b) Percent of Class as of December 31, 2023: Armistice Capital, LLC - 8.51% Steven Boyd - 8.51% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote Armistice Capital, LLC - 0 Steven Boyd - 0 (ii) Shared power to vote or to direct the vote Armistice Capital, LLC - 4,650,000 Steven Boyd - 4,650,000 (iii) Sole power to dispose o